Evidence map›Paper›PMID 40619405›Full record

ArticleBreast cancer research : BCR2025

Hsp47 drives obesity-associated breast cancer progression by enhancing asporin deposition in adipose tissue.

Gaofeng Xiong, Daheng He, Dana Napier, Jing Chen, Haizhu Shi, Chun Li, Paula J Hurley, Chi Wang, Haining Zhu, Changcheng Zhou and 2 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gaofeng XiongMarkey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
Daheng HeMarkey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
Dana NapierDepartment of Pathology, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
Jing ChenDepartment of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
Haizhu ShiMarkey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
Chun LiMarkey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
Paula J HurleyDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Chi WangMarkey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
Haining ZhuDepartment of Molecular and Cellular Biochemistry, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.
Changcheng ZhouDivision of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, 92521, USA.
Theresa J BocklageMarkey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA.
Ren XuMarkey Cancer Center, University of Kentucky, Lexington, KY, 40536, USA. ren.xu2010@uky.edu.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Role of PXR in EDC-induced cardiovascular diseaseR35ES035015 · NIEHS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Changcheng Zhou · 2023 to 2026
$3.4M
Roles of Hsp47 in Breast Cancer ProgressionR01CA207772 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI XU, REN · 2017 to 2025
$3.1M
Role of PXR in drug-elicited cardiovascular diseaseR01HL167206 · NHLBI · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Hong Chen, Changcheng Zhou · 2023 to 2026
$2.8M
Regulation of Metastatic Development by Heritable Variants in the Tumor MicroenvironmentR01CA211695 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HURLEY, PAULA JILL · 2018 to 2023
$1.9M
Roles of RORalpha in breast cancer development and progressionR01CA215095 · NCI · UNIVERSITY OF KENTUCKY · PI XU, REN · 2017 to 2022
$1.7M
Defining Tumor Microenvironmental Mediators of Prostate Cancer Metastasis and Therapy ResistanceR01CA285780 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paula Jill Hurley · 2024 to 2026
$1.7M
Roles of mRNA Transfer in Cancer Cell-Platelet CommunicationR01CA277946 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI XU, REN · 2023 to 2025
$1.2M
The PLOD2/succinate axis in regulating cancer cell plasticity and stemnessR01CA274981 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI XU, REN · 2023 to 2025
$1.1M
Role of P4HA1 in Endocrine Resistance of Breast CancerR21AG080176 · NIA · UNIVERSITY OF KENTUCKY · PI XIONG, GAOFENG · 2023 to 2024
$426k
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA207772NCI NIH HHS R01 CA211695NCI NIH HHS R01 CA215095NCI NIH HHS R01 CA274981NCI NIH HHS R01 CA277946NCI NIH HHS R01 CA285780NHLBI NIH HHS R01 HL167206NIA NIH HHS R21 AG080176NIEHS NIH HHS R35 ES035015NIH HHS R01CA207772, R01CA277946, R01CA274981NIH HHS R01CA211695NIH HHS R21AG080176
6 · The paper itself

Abstract

Fibrosis is an important feature of adipose tissue in obese individuals; nevertheless, roles of obesity-associated extracellular matrix (ECM) deposition in breast cancer progression largely remain elusive. Here, we show that expression of Hsp47, a chaperone protein involving collagen secretion, is induced in adipose tissue from obese humans and mice. Adipocyte-specific Hsp47 deletion (Adi-KO) suppresses the high-fat diet (HFD)-induced obesity and mammary tumor progression, accompanied by a reduction in ECM deposition. Matrisome analyses lead to the identification of asporin as a new target of Hsp47 in adipose tissue. Co-immunoprecipitation results confirm that the recruitment of Hsp47 enhances asporin secretion in adipocytes. We further show that knockout of asporin suppresses HFD-induced mammary tumor growth, while exogenous of asporin partially rescues tumor growth in the decellularized mammary gland derived from Hsp47 Adi-KO mice. These results indicate that asporin at least partially mediates Hsp47 function in HFD-associated tumor progression. Digital spatial profiling (DSP) analyses show that Hsp47 depletion significantly increases the accumulation of CD8 T cells in tumor and tumor-associated adipose tissues. These results implicate that Hsp47, along with-it mediated ECM deposition, suppresses the anti-tumor immunity under HFD conditions. These findings reveal Hsp47 as a novel target for mitigating obesity-associated breast cancer progression.

Indexed as

Adipose TissueBreast NeoplasmsExtracellular Matrix ProteinsHSP47 Heat-Shock ProteinsObesityAdipocytesAnimalsDiet, High-FatDisease ProgressionExtracellular MatrixFemaleHumansMiceMice, KnockoutASPN protein, humanExtracellular Matrix ProteinsHSP47 Heat-Shock Proteins

Identifiers

PMID40619405
PMCPMC12232796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.